GYRE THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Gyre Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2014 to Q2 2024.
  • Gyre Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $16K, a 82% decline year-over-year.
  • Gyre Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $7.01M, a 45.3% decline year-over-year.
  • Gyre Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7.28M, a 45.5% decline from 2022.
  • Gyre Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13.4M, a 293% increase from 2021.
  • Gyre Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3.41M, a 6.12% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $7.01M $16K -$73K -82% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $7.08M $11K -$199K -94.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $7.28M $6.88M -$5.4M -43.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $12.7M $98K -$126K -56.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-26
Q2 2023 $12.8M $89K -$257K -74.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $13.1M $210K -$305K -59.2% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $13.4M $12.3M +$11.6M +1698% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $1.77M $224K -$489K -68.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 $2.26M $346K -$637K -64.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $2.89M $515K -$511K -49.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $3.41M $683K -$237K -25.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $3.64M $713K -$355K -33.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $4M $983K +$149K +17.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $3.85M $1.03M +$221K +27.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $3.63M $920K +$249K +37.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $3.38M $1.07M +$267K +33.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $3.11M $834K -$69K -7.64% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $3.18M $805K -$24K -2.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $3.2M $671K -$76K -10.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 $3.28M $801K +$99K +14.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $3.18M $903K +$352K +63.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $2.83M $829K +$223K +36.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $2.61M $747K +$440K +143% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-20
Q3 2018 $2.17M $702K +$377K +116% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $1.79M $551K +$440K +396% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $1.35M $606K +$486K +405% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $863K $307K +$178K +138% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-08
Q3 2017 $685K $325K +$137K +72.9% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $548K $111K -$54K -32.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $602K $120K -$33K -21.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $635K $129K -$60K -31.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-19
Q3 2016 $695K $188K +$136K +262% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $559K $165K +$124K +302% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $435K $153K +$109K +248% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $326K $189K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-08
Q3 2015 $52K -$4K -7.14% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $41K -$20K -32.8% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-04
Q1 2015 $44K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q3 2014 $56K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-05
Q2 2014 $61K Apr 10, 2014 Jun 30, 2014 8-K/A 2015-10-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.